Need Help?

Transcriptomic characterization of breast cancer cells in a luminal-hybrid state

Background: We have previously identified a subset of early human breast epithelial progenitors that, despite their luminal affiliation, are enriched for basal markers, including CD146 and keratin 14 (K14). This simultaneous presence of both lineages thus defines a luminal-hybrid state. As luminal progenitors are generally proposed as a cell of origin of breast carcinoma, we examined how cells within this luminal hybrid state relate to breast cancer malignancy. Findings: We first analyzed two patient-derived xenograft (PDX)-derived breast cancer cell lines by dividing cell populations based on CD146-expression by FACS and found that this marker defines a cellular state with increased expression of a selection of luminal hybrid markers, including KRT14. When subjecting the sorted cells to in vitro transwell filter analysis, CD146HI/K14HI luminal hybrid state cells were less invasive. Knocking out either CD146- or K14-expression by CRISPR/Cas9 on a CD146/K14-positive background did not affect the in vivo tumorigenic potential, nor the differentiation state. However, when subjecting the respective sorted populations to a soft agar colony formation assay or as in vivo xenografts, CD146HI/K14HI cells exhibited more growth and metastasis, suggesting that the luminal hybrid state contributes to malignant properties. Conclusions: Our findings demonstrate that multiple components of the luminal hybrid state provide distinct properties to tumor malignancy. The fact that breast cancer can reflect a significant part of the original breast gland differentiation hierarchy may add weight to the argument that the search for novel strategies for treating basal-like breast cancer should include manipulation of cellular differentiation states.

Request Access

Data access committee for studying human normal breast cells from reduction mammoplasty tissue

This Data Access Committee (DAC) will evaluate any request provided by a requestor, and grant access to specific datasets to those who fulfill the criteria for data access within EGA. The Data Access Committee (DAC) will aim to respond to all initial requests within 2 weeks. The committee will check that requestors data/EGAD number is consistent with the current data submission (that requestor has contacted the correct DAC). Requestor has to sign up to the terms within the DAA in order to validate that the data are used within terms of consent, and document this to the committee. Requestor has to provide a valid Institutional email address as well as a valid affiliation to an institutional organization. Requestor has to document to be “appropriately qualified/bona fide” for use of the data.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS50000001972 RNASeq

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
EGAF50000928559 fastq 3.9 GB
EGAF50000928560 fastq 3.9 GB
EGAF50000928561 fastq 2.7 GB
EGAF50000928562 fastq 2.9 GB
EGAF50000928563 fastq 4.2 GB
EGAF50000928564 fastq 4.2 GB
EGAF50000928565 fastq 4.2 GB
EGAF50000928566 fastq 4.2 GB
EGAF50000928567 fastq 4.3 GB
EGAF50000928568 fastq 4.3 GB
EGAF50000928569 fastq 4.2 GB
EGAF50000928570 fastq 4.2 GB
EGAF50000928571 fastq 4.3 GB
EGAF50000928572 fastq 4.3 GB
EGAF50000928573 fastq 2.8 GB
EGAF50000928574 fastq 2.9 GB
EGAF50000928575 fastq 4.3 GB
EGAF50000928576 fastq 4.3 GB
EGAF50000928577 fastq 2.7 GB
EGAF50000928578 fastq 2.8 GB
EGAF50000928579 fastq 2.7 GB
EGAF50000928580 fastq 2.9 GB
EGAF50000928581 fastq 4.2 GB
EGAF50000928582 fastq 4.2 GB
24 Files (89.7 GB)